EA200200410A1 - Фибринолитически активный полипептид - Google Patents

Фибринолитически активный полипептид

Info

Publication number
EA200200410A1
EA200200410A1 EA200200410A EA200200410A EA200200410A1 EA 200200410 A1 EA200200410 A1 EA 200200410A1 EA 200200410 A EA200200410 A EA 200200410A EA 200200410 A EA200200410 A EA 200200410A EA 200200410 A1 EA200200410 A1 EA 200200410A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active polypeptide
fibrinolytically active
fibrinolytically
thrombolysis
applicable
Prior art date
Application number
EA200200410A
Other languages
English (en)
Other versions
EA005944B1 (ru
Inventor
Томас Чарльз Бун
Хуимин Ли
Майкл Бенджамин Манн
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200200410A1 publication Critical patent/EA200200410A1/ru
Publication of EA005944B1 publication Critical patent/EA005944B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описаны фибринолитически активный полипептид металлопротеиназы (называемый «тромболитик нового действия»), который применим для фибринолиза in vivo, и способы и материалы для его получения с помощью рекомбинантной экспрессии.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200410A 1999-10-01 2000-09-29 Фибринолитически активный полипептид EA005944B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,329 US6261820B1 (en) 1999-10-01 1999-10-01 Fibronolytically active polypeptide
PCT/US2000/027029 WO2001025445A1 (en) 1999-10-01 2000-09-29 Fibrinolytically active polypeptide

Publications (2)

Publication Number Publication Date
EA200200410A1 true EA200200410A1 (ru) 2002-10-31
EA005944B1 EA005944B1 (ru) 2005-08-25

Family

ID=23628486

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200200410A EA005944B1 (ru) 1999-10-01 2000-09-29 Фибринолитически активный полипептид
EA200400290A EA006487B1 (ru) 1999-10-01 2000-09-29 Фибринолитически активный полипептид

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200400290A EA006487B1 (ru) 1999-10-01 2000-09-29 Фибринолитически активный полипептид

Country Status (29)

Country Link
US (4) US6261820B1 (ru)
EP (2) EP1224298B1 (ru)
JP (1) JP2003511034A (ru)
KR (2) KR100700753B1 (ru)
CN (2) CN100357430C (ru)
AT (1) ATE292180T1 (ru)
AU (1) AU767827B2 (ru)
BG (1) BG106577A (ru)
BR (1) BR0014414A (ru)
CA (1) CA2386185A1 (ru)
CZ (1) CZ298502B6 (ru)
DE (1) DE60019147T2 (ru)
DK (1) DK1224298T3 (ru)
EA (2) EA005944B1 (ru)
ES (1) ES2240167T3 (ru)
HK (1) HK1049351B (ru)
HU (1) HUP0202650A3 (ru)
IL (1) IL148787A0 (ru)
MX (1) MXPA02003126A (ru)
NO (1) NO20021501L (ru)
NZ (1) NZ517951A (ru)
PL (1) PL355017A1 (ru)
PT (1) PT1224298E (ru)
RS (1) RS20060033A (ru)
SG (1) SG127720A1 (ru)
SK (1) SK4232002A3 (ru)
WO (1) WO2001025445A1 (ru)
YU (2) YU59604A (ru)
ZA (1) ZA200202206B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6523647B2 (en) * 2001-05-21 2003-02-25 Hydro Mobile Inc. Elevating platform assembly
AU2003215119B2 (en) * 2002-02-11 2008-11-20 Gold-T Tech, Inc. Method for preventing thrombus formation
US7016409B2 (en) * 2003-11-12 2006-03-21 Sony Corporation Apparatus and method for use in providing dynamic bit rate encoding
ES2239532B1 (es) * 2004-02-06 2006-11-01 Proyecto De Biomedicina Cima S.L. Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20070141625A1 (en) * 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
US20070225749A1 (en) 2006-02-03 2007-09-27 Martin Brian B Methods and devices for restoring blood flow within blocked vasculature
EP2403583B1 (en) 2009-03-06 2016-10-19 Lazarus Effect, Inc. Retrieval systems
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
US9260753B2 (en) 2011-03-24 2016-02-16 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
JP2017532024A (ja) 2014-09-09 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド コンポジット単一細胞核酸分析のための液滴ベースの方法および機器
WO2016130647A1 (en) 2015-02-11 2016-08-18 Lazarus Effect, Inc. Expandable tip medical devices and methods
EP3268462B1 (en) 2015-03-11 2021-08-11 The Broad Institute, Inc. Genotype and phenotype coupling
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
WO2017075297A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. High-throughput dynamic reagent delivery system
US12071663B2 (en) 2016-01-15 2024-08-27 Massachusetts Institute Of Technology Semi-permeable arrays for analyzing biological systems and methods of using same
US11072816B2 (en) 2017-05-03 2021-07-27 The Broad Institute, Inc. Single-cell proteomic assay using aptamers

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
DE3330699A1 (de) * 1983-08-25 1985-03-07 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
JPH05184352A (ja) * 1990-01-16 1993-07-27 Centro De Ing Genetica Y Biotecnol ピヒア パストリス（Ｐｉｃｈｉａ ｐａｓｔｏｒｉｓ）酵母中での異種遺伝子の発現方法、発現ベクターおよび形質転換微生物
US5709676A (en) 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
AU692497B2 (en) 1993-12-17 1998-06-11 Asahi Kasei Pharma Corporation Soluble thrombomodulin-containing pharmaceutical composition
US5626564A (en) 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US6020181A (en) 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
NZ505584A (en) 1996-05-24 2002-04-26 Univ British Columbia Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) * 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
WO1999029838A1 (en) * 1997-12-09 1999-06-17 Bristol-Myers Squibb Company Fibrinogen-converting enzyme hybrids
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
AU2001281081A1 (en) 2000-08-03 2002-02-18 Zymogenetics Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12

Also Published As

Publication number Publication date
EA006487B1 (ru) 2005-12-29
WO2001025445A1 (en) 2001-04-12
EP1605049A3 (en) 2006-12-13
YU22502A (sh) 2005-07-19
KR100700753B1 (ko) 2007-03-28
BR0014414A (pt) 2002-06-11
HK1049351B (zh) 2005-07-29
DE60019147D1 (en) 2005-05-04
BG106577A (bg) 2003-04-30
US6261820B1 (en) 2001-07-17
RS20060033A (sr) 2006-12-15
HK1049351A1 (en) 2003-05-09
CN101230340A (zh) 2008-07-30
SK4232002A3 (en) 2003-09-11
HUP0202650A3 (en) 2005-01-28
ATE292180T1 (de) 2005-04-15
JP2003511034A (ja) 2003-03-25
PL355017A1 (en) 2004-03-22
DK1224298T3 (da) 2005-05-30
US6617145B2 (en) 2003-09-09
PT1224298E (pt) 2005-06-30
HUP0202650A2 (hu) 2002-12-28
CN100357430C (zh) 2007-12-26
US20020058322A1 (en) 2002-05-16
YU59604A (sh) 2005-11-28
US20030186422A1 (en) 2003-10-02
EP1224298B1 (en) 2005-03-30
CA2386185A1 (en) 2001-04-12
AU767827B2 (en) 2003-11-27
SG127720A1 (en) 2006-12-29
CZ298502B6 (cs) 2007-10-24
KR20020047208A (ko) 2002-06-21
US7195903B2 (en) 2007-03-27
ZA200202206B (en) 2002-12-24
NO20021501D0 (no) 2002-03-26
US20080058256A1 (en) 2008-03-06
EP1224298A1 (en) 2002-07-24
MXPA02003126A (es) 2002-09-30
NZ517951A (en) 2004-02-27
ES2240167T3 (es) 2005-10-16
EP1605049A2 (en) 2005-12-14
NO20021501L (no) 2002-05-31
DE60019147T2 (de) 2006-05-11
CZ20021034A3 (cs) 2003-06-18
EA200400290A1 (ru) 2005-02-24
KR20060114034A (ko) 2006-11-03
KR100711312B1 (ko) 2007-04-27
EA005944B1 (ru) 2005-08-25
IL148787A0 (en) 2002-09-12
AU7625400A (en) 2001-05-10
CN1402788A (zh) 2003-03-12

Similar Documents

Publication Publication Date Title
EA200200410A1 (ru) Фибринолитически активный полипептид
FI911049A0 (fi) Vaevnadsplasminogenaktivator med zymogena eller fibrinspecifika egenskaper.
Andreasen et al. Inactive proenzyme to tissue‐type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
BR9814236A (pt) Enzima subtilase, sua variante, sequência de dna isolada, vetor de expressão, célula microbiana hospedeira, processo para produzir uma subtilase ou uma variante de subtilase, composição, e, uso de uma subtilase ou de uma variante de subtilase.
ATE355355T1 (de) Subtilasen der i-s1 und i-s2 untergruppen mit einem zusätzlichen aminosäurerest in der aktiven seitenschleifenregion
Wang et al. Purification and characterization of a novel fibrinolytic enzyme from Streptomyces spp.
Klose et al. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells
FI921847A (fi) Farmaceutisk komposition som har endoproteolytisk aktivitet, foerfarande foer endoproteolytisk behandling av (prekursor)proteiner samt foerfarande foer (mikro)bio- logisk framstaellning av proteiner.
ATE342965T1 (de) Subtilase enzyme der i-s1 und is2 untergruppen, mit einem zusätzlichen aminosaürerest in einer aktiven schleifenregion
Arza et al. Prostromelysin‐1 (proMMP‐3) stimulates plasminogen activation by tissue‐type plasminogen activator
EA200001050A1 (ru) Малеат пароксетина
ATE339496T1 (de) Modulation von gamma-secretase aktivität
EA200100501A1 (ru) Схема обезболивания
DK177791A (da) Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym
ES2110744T3 (es) Agentes de lavado enzimaticos.
Sanchez Mutalysins
ATE114170T1 (de) Substitutionsvariante des gewebeplasminogenaktivators.
EA200300502A1 (ru) СПОСОБЫ КРУПНОМАСШТАБНОГО ПРОИЗВОДСТВА ВЫВЕДЕННЫХ ИЗ РЕКОМБИНАНТНОЙ ДНК МОЛЕКУЛ tPA ИЛИ K2S
김정윤 et al. Isolation and characterization of a 32-kDa fibrinolytic enzyme (FE-32kDa) from Gloydius blomhoffii siniticus venom

Legal Events

Date Code Title Description
FA9A Withdrawal of a eurasian application
NF9A Restoration of lapsed right to a eurasian application

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU